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Regression of Kaposi’s Sarcoma and Improvement of Performance Status by a 
Combined Interferon B and Zidovudine Therapy in AIDS Patients 
To the Editor: 
We report five cases of HIVl-infected patients with Kaposi’s sar- 
coma (KS) (stadium WR6), who were treated with human fibro- 
blast interferon 13 (INF-B, Dr. Rentschler, Laupheim, FRG) and 
Zidovudine for a period of four months. One patient was transmit- 
ted into the hospital because of pneumocystis carinii infection and 
another because of salmonella Restock septicaemia. Both of them 
showed a Karnofski index of 20% [l], and developed Kaposi’s sar- 
coma while they stayed in the hospital. Three other patients had 
previously developed Kaposi’s sarcoma and showed a Karnofski 
index of 40%. KS, histologically verified, were localized at the hard 
palate, gum, at the plantar side of the feet, at the abdomen, and on 
the arms; one patient showed an additional lesion on the glans penis. 
In the last two months before therapy all patients had lost 4- 10 kg 
of body weight (bw), and helper cells ranged from 30 (in two pa- 
tients) to 180 with a mean of 120 cells ,&‘. 
INF-fl therapy was started by administering lo6 U/ 15 kg b.w. iv. 
daily for two periods of 14 d each, with an interruption of 14 d. 
After the second course we administered a constant dose of lo6 U/ 
15 kg b.w. every third day. Only minimal side effects were observed 
such as low-grade fever after infusion, which was successfully 
treated by Paracetamol administration before the next infusion was 
started. Zidovudine (4 X 200 mg) had been given daily three 
months before and during treatment with interferon-g therapy. 
All patients showed a significant and persistent regression of the 
number and diameter of KS after the first treatment period. The KS 
lesions in the mouth and at the plantar side of the feet disappeared, 
the other lesions became smaller and changed their color from dark 
to bright red, similar to the initial stages of KS lesions. 
There was a weight gain in all patients with a mean of 9 kg and a 
small increase in helper cells to a mean value of 160 cells&’ (range 
of 80-300); the Karnofski index changed to 90% (minor disease 
symptoms). All patients have returned to work now. 
Previous results show that INF therapy may cause a regression of 
KS [2,3] and an improvement of the performance status [4]. Our 
findings with interferon-l3 therapy show more clearly the effective- 
ness of INF therapy. Indeed the number and diameter of the KS 
lesions was definitely reduced and the performance status improved. 
Norbert H. Brockmeyer, M.D. 
Lutz Mertins, M.D. 
Christiane Daecke, cand. med. 
Manfred Goos, M.D. 
Department of Dermatology, 
University of Essen, 
Essen, FRG 
REFERENCES 
1. Karnofski DA, Abelmann WH, Carver LF, Burchenal JH. The use of 
the nitrogen mustards in the palliative treatment of carcinoma. 
Cancer 1:634-56, 1948 
2. Gelman EP, Preble 0, Steis R, et al: Treatment of Kaposi’s sarcoma with 
alpha-interferon (Wellferon). Chn Res 32:415-417, 1984 
3. Krown SE, Real FX, Vadhan-Raj S, et al: Raposi’s sarcoma and the 
acquired immune deficiency syndrome. Treatment with recombinant 
interferon Alpha and analysis of prognostic factors. Cancer 
57(Suppl):1662-1664, 1986 
4. Val Hutchinson, Cummins JM: Low-dose oral interferon in patients 
with AIDS. Lancet ii:1530-31, 1987 
